Antimuscarinic agents: Implications and concerns in the management of overactive bladder in the elderly

Clinical Therapeutics

Volumn 27, Issue 1, 2005, Pages 127-138

  Kay, Gary G ^a,c   Granville, Lisa J ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c Washington Neuropsychological Institute   (United States)

Author keywords

Adverse effects; Anticholinergic; Antimuscarinic; Elderly; Overactive bladder

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DICYCLOVERINE; EYE DROPS; HYOSCYAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPANTHELINE BROMIDE; PROPIVERINE; SCOPOLAMINE; SPASMOLYTIC AGENT; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE;

AGING; ANAMNESIS; ANTICHOLINERGIC EFFECT; BLOOD BRAIN BARRIER; BRAIN DYSFUNCTION; CAREGIVER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONSULTATION; DELIRIUM; DETRUSOR MUSCLE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; ELECTROENCEPHALOGRAM; EXAMINATION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEALTH EDUCATION; HUMAN; INCONTINENCE; INFORMATION RETRIEVAL; INVOLUNTARY MOVEMENT; LEARNING TEST; MEDICAL SOCIETY; MEDLINE; MEMORY DISORDER; NONHUMAN; OVERACTIVE BLADDER; POPULATION; PRESCRIPTION; PREVALENCE; PRURITUS; PUBLICATION; QUALITY OF LIFE; RECEPTOR AFFINITY; RECOGNITION; REM SLEEP; REVIEW; VISUAL IMPAIRMENT; XEROSTOMIA;

AGED; BLOOD-BRAIN BARRIER; CLINICAL TRIALS; HUMANS; MUSCARINIC ANTAGONISTS; RECEPTOR, MUSCARINIC M1; URINARY INCONTINENCE;

EID: 14844320094     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.01.006     Document Type: Article

References (84)

1. Andersson K.E. Antimuscarinics for treatment of overactive bladder Lancet Neurol 3 2004 46 53
2. Wein A.J. Diagnosis and treatment of the overactive bladder Urology 62 Suppl 2 2003 20 27
3. Ouslander J.G. Management of overactive bladder N Engl J Med 350 2004 786 799
4. Flicker C., Ferris S.H., and Serby M. Hypersensitivity to scopolamine in the elderly Psychopharmacology (Berl) 107 1992 437 441
5. Stewart W.F., Van Rooyenj B., and Cundiff G.W. Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327 336
6. Abrams P., Cardozo L., and Fall M. Standardisation Sub-committee of the International Continence Society The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International ContinenceSociety Neurourol Urodyn 21 2002 167 178
7. Nitti V.W. Clinical impact of overactive bladder Rev Urol 4 Suppl 4 2002 S2 S6
8. Abrams P., and Wein A.J. Introduction: Overactive bladder and its treatments Urology 55 2000 1 2
9. Abrams P., Kelleher C.J., Kerr L.A., and Rogers R.G. Overactive bladder significantly affects quality of life Am J Manag Care 6 Suppl 11 2000 S580 S590
10. Hashim H., and Abrams P. Drug treatment of overactive bladder: Efficacy, cost and quality-of-life considerations Drugs 64 2004 1643 1656
11. [published correction appears in BJU Int. 2001;88:807] Milsom I., Abrams P., and Cardozo L. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760 766
12. Kobelt G., Kirchberger I., and Malone-Lee J. Review. Quality-oflife aspects of the overactive bladder and the effect of treatment with tolterodine BJU Int. 83 1999 583 590
13. Liberman J.N., Hunt T.L., and Stewart W.F. Health-related quality of life among adults with symptoms of overactive bladder: Results from a U.S. community-based survey Urology 57 2001 1044 1050
14. Keller S.L. Urinary incontinence: Occurrence, knowledge, and attitudes among women aged 55 and older in a rural Midwestern setting J Wound Ostomy Continence Nurs 26 1999 30 38
15. Wein A.J., and Rovner E.S. The overactive bladder: An overview for primary care health providers Int J Fertil Womens Med 44 1999 56 66
16. Bulmer P., and Abrams P. The unstable detrusor Urol Int 72 2004 1 12
17. Andersson K.E., and Yoshida M. Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Eur Urol 43 2003 1 5
18. Andersson K.E. Bladder activation: Afferent mechanisms Urology 59 Suppl 1 2002 43 50
19. Scarpero H.M., and Dmochowski R.R. Muscarinic receptors: What we know Curr Urol Rep 4 2003 421 428
20. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo Br J Pharmacol 120 1997 1409 1418
21. 5 Muscarinic receptor distribution in rat CNS by RT PCR and HPLC J Neurochem 63 1994 815 821
22. 1 muscarinic receptor mutant mice Nat Neurosci 6 2003 51 58
23. 1 knockout mice Life Sci 68 2001 2489 2493
24. Starr J.M., Wardlaw J., and Ferguson K. Increased bloodbrain barrier permeability in type II diabetes demonstrated bygadolinium magnetic resonance imaging J Neurol Neurosurg Psychiatry 74 2003 70 76
25. Liebsch R., Kornhuber M.E., and Died D. Blood-CSF barrier integrity in multiple sclerosis Acta Neurol Scand 94 1996 404 410
26. Bake S., and Sohrabji F. 17beta-Estradiol differentially regulates blood-brain barrier permeability in young and aging female rats Endocrinology 145 2004 5471 5475
27. Pakulski C., Drobnik L., and Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier Med Sci Monit 6 2000 314 318
28. Feinberg M. The problems of anticholinergic adverse effects in older patients Drugs Aging 3 1993 335 348
29. Available at: Oxford Centre for Evidence-Based Medicine Levels of evidence and grades of recommendation Accessed October 17, 2004
30. Available at Andersson K.E., Appell R., and Awad S. Pharmacological treatment of urinary incontinence Accessed Abrams P. Andersson K.E. Artibani W. 2nd International Consultation on Incontinence. Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence November 23, 2004
31. Ditropan XL (oxybutynin chloride extended release tablets 5 mg and 10 mg) November 23, 2004
32. Yarker Y.E., Goa K.L., and Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging 6 1995 243 262
33. Birns J., Lukkari E., and Malone-Lee J.G. A randomized controlled trial comparing the efficacy of controlled release oxybutynin tablets (10 mg once daily) with conventional oxybutynintablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxyburynin BJU Int 85 2000 793 798
34. Davila G.W., Daugherty C.A., Sanders S.W. Transdermal Oxybutynin Study Group A short-term, multi center, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal comparedto immediate release oral oxyburynin treatment of patients with urge urinary incontinence J Urol 166 2001 140 145
35. Dmochowski R.R., Davila G.W., Zinner N.R. Transdermal Oxybutynin Study Group Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence J Urol 168 2002 580 586
36. Clemett D., and Jarvis B. Tolterodine: A review of its use in the treatment of overactive bladder Drugs Aging 18 2001 277 304
37. van Kerrebroeck P., Kreder K., Jonas U. Tolterodine Study Group Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder Urology 57 2001 414 421
38. Diokno A.C., Appell R.A., Sand P.K. OPERA Study Group Prospective, randomized, doubleblind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial Mayo Clin Proc 78 2003 687 695
39. Rovner E.S., and Wein A.J. Update on overactive bladder: Pharmacologic approaches on the horizon Curr Urol Rep 47 2003 385 390
40. Hofner K., Halaska M., and Primus C. Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: A double-blind, controlled, multicentre clinical trial Neurourol Urodyn 19 2000 487 488
41. Jünemann K., and Al-Shukri S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: A double-blind, placebo-controlled, multicentre clinical trial Neurourol Urodyn 19 2000 488 490
42. Hegde S.S., Mammen M., and Jasper J.R. Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies Curr Opin Invest Drugs 5 2004 40 49
43. 3 receptor subtype Presented at: 32nd Annual Meeting of the International Continence Society August 28-30, 2002
44. Ikeda K., Kobayashi S., and Suzuki M. M(3) Receptor antagonism by the novel antimuscarinic agent solifen acin in the urinary bladder and salivary gland Naunyn Schmiedebergs Arch Pharmacol 366 2002 97 103
45. Haab F., Stewart L., and Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well tolerated once-daily treatment for overactive bladder Eur Urol 45 2004 420 429
46. Levey A.I., Kitt C.A., and Simonds W.F. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies J Neurosci 11 1991 3218 3226
47. 1 receptor in regulating circadian rhythms Life Sci 68 2001 2467 2472
48. De Rosa E., and Hasselmo M.E. Muscarinic cholinergic neuromodulation reduces proactive interference between stored odor memories during associative learning in rats Behav Neurosci 114 2000 32 41
49. Atri A., Sherman S., and Norman K.A. Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired-associate memory task Behav Neurosci 118 2004 223 236
50. Hasselmo M.E. Neuromodulation: Acetylcholine and memory consolidation Trends Cogn Sci 3 1999 351 359
51. Sperling R., Greve D., and Dale A. Functional MRI detection of pharmacologically induced memory impairment Proc Natl Acad Sci U S A 99 2002 455 460
52. [published correction appears in Arch Intern Med. 2004;164:298] Fick D.M., Cooper J.W., and Wade W.E. Updating the Beers criteria for potentially inappropriate medi cation use in older adults: Results of a US consensus panel of experts Arch Intern Med 163 2003 2716 2724
53. White P., Hiley C.R., and Goodhardt M.J. Neocortical cholinergic neurons in elderly people Lancet 1 1977 668 671
54. Kawas C.H., and Brookmeyer R. Aging and the public health effects of dementia N Engl J Med 344 2001 1160 1161
55. 11C]methyl-4-piperidyl benzilate combined with cerebral blood flow measurement in conscious monkeys Brain Res 916 2001 22 31
56. Nicolle M.M., Gallagher M., and McKinney M. Visualization of muscarinic receptor-mediated phosphoinosi tide turnover in the hippocampus of young and aged, learningimpaired Long Evans rats Hippocampus 11 2001 741 746
57. Blazer D.G. II, Federspiel C.F., Ray W.A., and Schaffner W. The risk of anticholinergic toxicity in the elderly: A study of prescribing practices in two populations J Gerontol 38 1983 31 35
58. Johnson A.L., Hollister I.T., and Berger P.A. The anticholinergic intoxication syndrome: Diagnosis and treatment J Clin Psychiatry 42 1981 313 317
59. Tune L., Carr S., Hoag E., and Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium Am J Psychiatry 149 1992 1393 1394
60. Tune L.E. Anticholinergic effects of medication in elderly patients J Clin Psychiatry 62 Suppl 21 2001 11 14
61. Mulsant B.H., Pollock B.G., and Kirshner M. Serum anticholinergic activity in a community-based sam ple of older adults: Relationship with cognitive performance Arch Gen Psychiatry 60 2003 198 203
62. Mintzer J., and Burns A. Anticholinergic side-effects of drugs in elderly people J R Soc Med 93 2000 457 462
63. Monte Carlo, Monaco Kay G. The M(3) selective receptor antagonist darifenacin has no clinically relevant effect on cognition and cardiac function Poster presented at: 3rd International Consultation on Incontinence June 26-29, 2004
64. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport J Neurochem 70 1998 1781 1792
65. Habgood M.D., Begley D.J., and Abbott N.J. Determinants of passive drug entry into the central nervous system Cell Mol Neurobiol 20 2000 231 253
66. Physicians' Desk Reference 58th ed. 2004 Thomson Montvale, NJ
67. Todorova A., Vonderheid-Guth B., and Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system J Clin Pharmacol 41 2001 636 644
68. Oxybutynin chloride extendedrelease tablets 2004 ALZA Corporation Mountain View, Calif.
69. Trospium chloride 20 mg tablets 2004 Indevus Pharmaceuticals, Inc Lexington, Mass
70. Tolterodine tartrate tablets 2003 Pfizer Inc New York
71. Katz I.R., Sands L.P., and Bilker W. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride J Am Geriatr Soc 46 1998 8 13
72. Available at State of West Virginia Department of Health and Human Resources Medicaid Preferred Drug List-Phase I. Accessed November 24 2004
73. Available at: Indiana Health Coverage Programs Drug Utilization Review Board Provider Bulletin to All Pharmacy Provid ers and Prescribing Practitioners: Preferred Drug List-Re-review Accessed November 24, 2004
74. Available at State of Idaho Division of Medicaid Urinary Incontinence Drugs Prior Authorization Form Accessed November 24, 2004
75. Darifenacin extended-release tablets [package insert] 2004 Novartis International A.G. Basel, Switzerland
76. Diefenbach K., Donath F., and Maurer A. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers Clin Drug Invest. 23 2003 395 404
77. Abstract 140 Diefenbach K., Arold G., and Wollny A. The influence of anticholinergics used in incontinence treatment on sleep in healthy volunteers aged 50 years and older Presented at: International Continence Society Annual Meeting Paris, France August 25-27, 2004
78. 3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderlyvolunteers Eur Urol Suppl. 3 2004 131
79. Salom I.L., and Davis K. Prescribing for older patients: How to avoid toxic drug reactions Geriatrics 50 1995 37 45
80. Donnellan C.A., Fook L., McDonald P., and Playfer J.R. Oxybutynin and cognitive dysfunction BMJ 315 1997 1363 1364
81. Edwards K.R., and O'Connor J.T. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors J Am Geriatr Soc. 50 2002 1165 1166
82. Benedict R.H., Schretlen D., Groninger L., and Brandt J. Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability Clin Neuropsychologist 12 1998 43 55
83. Tsao J.W., and Heilman K.M. Transient memory impairment and hallucinations associated with tolterodine use N Engl J Med. 349 2003 2274 2275
84. Womack K.B., and Heilman K.M. Tolterodine and memory: Dry but forgetful Arch Neurol. 60 2003 771 773